AGP Picks
View all

Africa News Currents
Provided by AGP

Africa News Currents: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa News Currents.

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

July 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

Press releases published on May 7, 2026

GoldHaven Upsizes Flow-Through Financing to up to $1.2 Million on Strong Demand to Expand 2026 Drill Program at Magno
May 7, 2026

GoldHaven Upsizes Flow-Through Financing to up to $1.2 Million on Strong Demand to Expand 2026 Drill Program at Magno

Indeterminate GlobeNewswire
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 7, 2026

Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results

Indeterminate GlobeNewswire
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
May 7, 2026

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

Indeterminate GlobeNewswire
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
May 7, 2026

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

Indeterminate GlobeNewswire
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
May 7, 2026

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings

Indeterminate GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 7, 2026

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

Indeterminate GlobeNewswire
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
May 7, 2026

ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

Indeterminate GlobeNewswire
UroGen Pharma to Present at Upcoming Investor Conferences
May 7, 2026

UroGen Pharma to Present at Upcoming Investor Conferences

Indeterminate GlobeNewswire
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 7, 2026

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Indeterminate GlobeNewswire
SERB Pharmaceuticals Announces ThyroSafe 130 mg Potassium Iodide Tablets are Now Commercially Available in the US
May 7, 2026

SERB Pharmaceuticals Announces ThyroSafe 130 mg Potassium Iodide Tablets are Now Commercially Available in the US

Indeterminate GlobeNewswire
One Bullion Reports Gravity-Finish Assay Results at Vumba Project, Including 30.8 g/t Au, and Receives EIA Approval for Maitengwe Project
May 7, 2026

One Bullion Reports Gravity-Finish Assay Results at Vumba Project, Including 30.8 g/t Au, and Receives EIA Approval for Maitengwe Project

Indeterminate GlobeNewswire
Entrada Therapeutics Reports First Quarter 2026 Financial Results
May 7, 2026

Entrada Therapeutics Reports First Quarter 2026 Financial Results

Indeterminate GlobeNewswire
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
May 7, 2026

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

Indeterminate GlobeNewswire
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
May 7, 2026

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

Indeterminate GlobeNewswire
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026

Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Indeterminate GlobeNewswire
Ligand Reports First Quarter 2026 Financial Results
May 7, 2026

Ligand Reports First Quarter 2026 Financial Results

Indeterminate GlobeNewswire
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
May 7, 2026

Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

Indeterminate GlobeNewswire
Drill Program is Underway at VR’s New Boston Moly-Tungsten-Copper-Silver Porphyry Project in Nevada
May 7, 2026

Drill Program is Underway at VR’s New Boston Moly-Tungsten-Copper-Silver Porphyry Project in Nevada

Indeterminate GlobeNewswire
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
May 7, 2026

Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

Indeterminate GlobeNewswire
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
May 7, 2026

Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Africa News Currents

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.